Shots:

• Biogen will utilize Envisagenics’ SpliceCore- an AI- driven RNA splicing platform to understand the regulation of different RNA isoforms in CNS cell types which will provide access to SpliceCore’s database of ~7M RNA splicing errors
• The collaboration will identify and validate disease genetic targets to increase the success rate in the CNS drug discovery
• The addition of Envisagenics’ machine learning algorithms and high-performance computing helps to identify- test- and validate splicing errors at a large scale

  Ref: GLOBE NEWSWIRE | Image: Biogen